Viemed (VMD) Q4 2025 earnings review
Diversification Pays Off with Record Top-Line and Free Cash Flow Surge
Viemed closed out 2025 with an exceptional quarter, posting record revenue of $76.2 million (+26% YoY) and net income of $5.6 million (+31% YoY). The company's strategic pivot to diversify beyond its core ventilation business is succeeding: the Sleep therapy and resupply segments grew at breakneck speed, and the newly integrated Lehan's acquisition provided a solid footing in Maternal Health. Crucially, as the capital-intensive ventilator fleet swap concluded, Free Cash Flow accelerated dramatically, jumping 141% for the full year to $28.1 million. While the changing product mix continues to weigh on gross margins, aggressive SG&A leverage and strong guidance for 2026 ($310-$320M in revenue) signal that the operational engine is firing efficiently.
🐂 Bull Case
Sleep therapy patients jumped 62% YoY, and resupply patients soared 49% YoY. This segment requires less capital infrastructure than the legacy vent business, dropping significant cash to the bottom line.
With the ventilator fleet upgrade program largely behind them, Net CAPEX plummeted as a percentage of revenue, causing Free Cash Flow to skyrocket 141% YoY. This pristine balance sheet funded the completion of a buyback, an acquisition, and the authorization of a new 5% share repurchase program.
🐻 Bear Case
The massive success of the lower-margin Sleep and Staffing businesses is structurally pushing gross margins down (58% in Q4 vs. historical norms of >60%). SG&A leverage must remain tight to protect the bottom line.
Despite strong YoY numbers, the active ventilator patient count actually dropped sequentially in Q4 (from 12,372 to 12,259), breaking a multi-year growth streak.
⚖️ Verdict: 🟢
Bullish. The thesis of becoming a diversified, clinical-first in-home care provider is being validated by the numbers. Triple-digit free cash flow growth and a healthy share buyback program provide an excellent floor for investors.
Key Themes
Accelerating Sleep and Resupply Volume
The sleep business continues to be Viemed's primary growth engine. PAP therapy patients reached 34,528 (+62% YoY), and Sleep Resupply patients hit 36,561 (+49% YoY). The resupply base now formally exceeds the therapy rental base, validating management's strategy to build a compounding, recurring revenue stream. This mix shift is also visible in the 'Equipment and supply sales' revenue line, which surged 62.7% for the full year.
Maternal Health Expansion via Lehan's
The acquisition of Lehan's Medical Equipment in Q3 2025 has successfully established a completely new growth vector. Maternal health already constitutes 3% of the company's FY25 revenue mix. Management intends to leverage its existing national payer contracts to scale this service beyond its current regional footprint in 2026.
Reversing CapEx Cycle Fuels Free Cash Flow
In previous quarters, capital expenditures were heavily elevated to fund an aggressive ventilator fleet upgrade. With that program completed by mid-2025, Net CapEx fell to 8.8% of revenue for the full year (down from 12.2% in 2024). This generated a massive Free Cash Flow inflection to $28.1 million, providing ample dry powder to fully eliminate net debt and execute a new share repurchase authorization.
Gross Margin Compression is Now Structural
Gross margins have settled into a stable but lower range (58% in Q4 vs 60% a year ago). This is a direct consequence of the company's success in non-ventilation services (Sleep, Resupply, and Staffing), which carry lower gross margins but require less CapEx. While the company is successfully offsetting this with SG&A leverage to protect EBITDA, any future inefficiency in operating expenses will directly hit the bottom line.
Core Ventilation Patient Count Unexpectedly Drops
While overall revenue was stellar, a concerning data point emerged in the foundational ventilator business. After 17 consecutive quarters of sequential growth celebrated earlier in the year, the active vent patient count dropped from 12,372 in Q3 to 12,259 in Q4. If the core higher-margin product line continues to contract sequentially, it will put even more pressure on the Sleep and Maternal divisions to carry the growth.
Macro Risk: The Return of Competitive Bidding
While immediate impacts are unlikely before 2027, the potential return of Medicare's competitive bidding program for Durable Medical Equipment (DME) remains a long-term overhang. Management's strategic diversification away from heavy Medicare reliance (now 38% of revenue vs 41% in 2024) is a direct, pre-emptive defense mechanism against this specific regulatory threat.
AI-Powered Revenue Cycle Management
Viemed is aggressively deploying Artificial Intelligence to manage the high-volume nature of its booming sleep business. Using AI for intake and revenue cycle processes has been crucial for achieving operational scale without bloating administrative headcount, leading to continued improvements in SG&A as a percentage of revenue.
Other KPIs
Accelerating. Up 21% YoY, comfortably beating the midpoint of the original $254-$265M guidance provided at the beginning of 2025. This reflects excellent organic execution and a half-year of acquired revenue from Lehan's.
Accelerating. Up 33% YoY. This marks the company's ninth consecutive year of positive net income, driven by robust top-line growth and stable operating leverage.
Stable and highly liquid. Despite closing a $26M acquisition and repurchasing $13.2M of stock during the year, Viemed closed 2025 with $13.5M in cash against only $11.3M in long-term debt, representing effectively zero net debt.
Guidance
Decelerating slightly. The midpoint ($315M) implies an approximate 16.5% YoY growth rate. While this is lower than FY25's 21% growth, it represents extremely robust performance on a larger base. Management expects Q1 to be flat to slightly down sequentially (typical seasonality), with growth accelerating from Q2 through Q4.
Decelerating. The midpoint ($67M) implies 9.1% YoY growth, significantly lagging the 16.5% top-line growth guidance. This confirms that the structural margin compression from the mix shift toward Sleep and Maternal health will persist throughout 2026, leading to an implied EBITDA margin of roughly 21.2% (down from 22.7% in FY25).
Stable. Translates to roughly $31M-$36M. This indicates a normalized run-rate following the completion of the ventilator upgrade cycle, allowing the company to maintain its high free cash flow conversion profile.
Key Questions
Sequential Vent Patient Decline
After years of consecutive quarterly growth, active ventilator patients dropped sequentially in Q4. Is this strictly a matter of temporary attrition, a change in provider referrals, or are we reaching a saturation point in your established markets?
EBITDA Margin Floor
With FY26 EBITDA guidance implying a margin contraction down to ~21%, where do you see the eventual 'floor' for consolidated EBITDA margins as Sleep, Staffing, and Maternal businesses make up a larger piece of the pie?
Maternal Health National Rollout
You've cited maternal health as a significant growth driver for 2026. Can you walk us through the actual timeline and capital requirements for taking the Lehan's maternal platform from a regional base to a fully national offering?
M&A Pipeline Priorities
With the new 5% share repurchase authorization acting as a solid floor for capital allocation, how does the current M&A pipeline look compared to last year? Are you prioritizing geographic expansion, or new product lines similar to the Lehan's deal?